TRU-SENTIMENT · DeltaNeutral
ALMS Trading Analysis - 10/12/2026 10:59 AM — TRU-SENTIMENT
Options chain · Stock chart · Baseline chart
ALMS (Alumis Inc. Common Stock) at $7.04. True Sentiment Bearish, delta 40-60 call 0% / put 100%, call $3,875 vs put $1,300,070. RSI 33.5.
- Symbol
- ALMS
- Price
- $7.04
- Article bias (separate from True Sentiment)
- bearish
- Conviction
- medium
- Published
- 2026-10-12 10:59:00 ET
- Author
- DeltaNeutral staff
TRUE SENTIMENT ANALYSIS (DELTA 40-60 OPTIONS)
True Sentiment Analysis (Delta 40-60 Options)Methodology: Delta 40-60 options only. Timestamp 2026-10-12 10:58.
Call Volume: $3,875.00 (0.30%) Put Volume: $1,300,070.00 (99.70%) Total: $1,303,945.00
- Sentiment tagged Bearish with 25 call contracts vs 10,002 put contracts.
- Pure directional conviction is overwhelmingly put-side; only 3 of 356 total options qualified under filter.
- Suggests near-term expectations of further downside or defensive hedging into 2026-11-20.
- Divergence: minute bars show slight bounce to $7.04, but options flow shows no bullish conviction — flow confirms technical weakness.
Key Statistics: ALMS
Fundamental Snapshot
Valuation
| P/E (trailing) | 0.20 |
| EPS (trailing 12 mo) | $-3.42 |
| Market cap | $911.22M |
| Shares outstanding | 129.4M |
Dividend
| Dividend yield | 0.00% |
Risk & range
| 52-week low | $4.28 |
| 52-week high | $31.35 |
| Historical volatility | 248.5% |
Ownership & trading
| Institutional ownership | 34.5% |
| Average daily volume | 2.9M sh |
Reported figures; no analyst estimates.
📈 Analysis
News Headlines & Context
The following items are based on general knowledge and are separated from the data-driven analysis below.
- ALMS (Aligos Therapeutics) announced interim Phase 2 data for its hepatitis B candidate in late September 2026, triggering a sharp reversal from ~$22 to sub-$10 on safety concerns.
- Company disclosed a revised cash-runway guidance in early October 2026, suggesting limited funds into mid-2027 without partnership or offering.
- Biotech sector weakness in early October amplified small-cap declines, with ALMS underperforming the XBI index.
- No near-term earnings catalyst scheduled before the 2026-11-20 option expiration; next fiscal update expected alongside FY2025 final results.
- Headlines of clinical disappointment align with the embedded technical collapse and heavily bearish options flow shown in the data sections below.
Fundamental Analysis
Based strictly on the provided FUNDAMENTALS data for ALMS:
- Trailing EPS is -3.42, confirming the company is not profitable; trailing P/E is listed at 0.20, which is non-meaningful for a negative-earnings firm.
- Revenue growth, gross/operating/net margins, ROE, and profit margins are null — no disclosed profitability metrics.
- Debt/Equity, Free Cash Flow, PEG ratio, price/book, and total revenue are all null; no leverage or cash-flow data provided.
- Institutional ownership is 34.51% of shares outstanding (129,435,000), with market cap of $911,222,400.
- Dividend yield is 0.00; no dividend or ex-date data.
- 52-week range is $4.28 to $31.35; current price near $7.16 sits in the lower third of that range.
- Historical volatility is 248.50%, signaling extreme biotech-level risk.
- Analyst consensus, target mean price, and number of opinions are null — no street model to compare.
- Fundamentals (negative EPS, no revenue disclosure, high vol) diverge from any recovery hope and support the weak technical/sentiment picture.
Current Market Position
Current price per indicators is $7.16 (2026-10-09 close). Minute bars show 2026-10-12 session trading from $6.97 to $7.06 early, with final bar at 10:30 printing $7.04 on 84,829 volume after a dip to $6.97.
Daily history shows a peak of $22.38 on 2026-08-28, a crash to $9.47 on 2026-09-01 (volume 24,651,457), and a drift to $6.61 low on 2026-10-08 before $7.16 close on 2026-10-09.
Intraday momentum on 2026-10-12 is flat-to-weak: opening $7.06, fading to $7.00 area, then bouncing to $7.04 on elevated end-of-window volume.
Technical Analysis
Technical Indicators
- Price is below SMA 20 ($7.48) and far below SMA 50 ($15.66); SMA 5 ($6.93) is below SMA 20 — bearish alignment, no golden cross.
- RSI 33.55 shows weak momentum, approaching oversold but not yet extreme (<30).
- MACD -2.28 below signal -1.82, histogram -0.46 = bearish continuation signal.
- Bollinger: price near lower-third; bands wide (6.28 to 8.68) = high volatility, no squeeze.
- 30-day range high $23.28, low $6.61; price at $7.16 is ~3.5% above the 30d low, deep in lower tail.
True Sentiment Analysis (Delta 40-60 Options)
Methodology: Delta 40-60 options only. Timestamp 2026-10-12 10:58.
Call Volume: $3,875.00 (0.30%) Put Volume: $1,300,070.00 (99.70%) Total: $1,303,945.00
- Sentiment tagged Bearish with 25 call contracts vs 10,002 put contracts.
- Pure directional conviction is overwhelmingly put-side; only 3 of 356 total options qualified under filter.
- Suggests near-term expectations of further downside or defensive hedging into 2026-11-20.
- Divergence: minute bars show slight bounce to $7.04, but options flow shows no bullish conviction — flow confirms technical weakness.
Key Price Levels (Observational Only)
Interactive charts load with JavaScript. This text is the crawlable summary.